Beximco Pharma marks breakthrough in global access by delivering affordable Cystic Fibrosis medicines to patients
Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company") today formally handed over TRIKOâ (a combination of elexacaftor, tezacaftor, and ivacaftor, also known as ETI), the low-cost generic version of the breakthrough cystic fibrosis (CF) treatment Trikaftaâ developed by US-based Vertex Pharmaceuticals, to patients and their representatives from six countries in a ceremony held at the Company’s manufacturing facility in Dhaka. The milestone marks the first time an affordable generic alternative to this life-changing medicine has been made available to CF patients globally.
The event was attended by selected patients and their representatives from the United States, United Kingdom, Slovakia, Qatar, South Africa, and Bangladesh, alongside representatives from the UK-based patient ...


